Vishal Patil1, Glyn Johnson1
1Radiology, NYU School of Medicine, New York, United States
DSC MRI measurements of relative cerebral blood volume, referenced to normal appearing white matter (NAWM), are frequently used in monitoring treatment response. Bevacizumab is the first FDA approved anti-angiogenic agent and has shown efficacy in glioma when used in combination with conventional cytotoxic agents. In this study we calculated NAWM CBV in three sets of patients groups; 1) never received bevacizumab, 2) received bevacizumab after initial diagnosis and 3) only after reoccurrence. Results show significant reductions in NAWM CBV after treatment with bevacizumab, suggesting that care need be exercised in the use of rCBV measurements to monitor treatment response.